



***Post-Transplant Lymphoproliferative Disorder
Externally led Patient Focused Drug Development Meeting
May 4, 2022***

- 12:30pm Welcome, Opening Remarks, and Meeting Overview
Debbie Drell, Director of Membership, NORD
Ariel Markowitz-Shulman, Associate Director of Strategic Planning, NORD
Peter Saltonstall, President & CEO, NORD
Swapna Kakani, patient advocate
- 12:45pm Clinical Overview of Post- Transplant Lymphoproliferative Disorder
Thomas M. Habermann, MD, Division of Hematology, Department of Medicine, Mayo Clinic
- 1:00pm Welcome Remarks
Nicole Gormley, MD, Director, Division of Hematology Malignancies II, FDA
- 1:10pm Overview of Discussion Format & Demographic Polling Questions
Debbie Drell, Director of Membership, NORD
Ariel Markowitz-Shulman, Associate Director of Strategic Planning, NORD
- 1:25pm Topic 1: Living with PTLD—Burdens and Symptoms

Ellen Keyser Endelman, patient
Sarah O'Connor, caregiver
Marianna DeLeon, patient
Rebekah Palmer, patient
Greg and Cyndi Tufaro, caregivers

- 1:50pm Polling Questions and Facilitated Audience Discussion on Topic 1
Debbie Drell, Director of Membership, NORD
Ariel Markowitz-Shulman, Associate Director of Strategic Planning, NORD
- 2:50pm Break
- 3:00pm Topic 2: Current & Future Treatments
Erin Tansey, caregiver
Swapna Kakani, patient
Brad Buchanan, patient
Michelle Pfab, caregiver
Ola Ojewumi, patient
- 3:30pm Polling Questions and Facilitated Audience Discussion on Topic 2
Debbie Drell, Director of Membership, NORD
Ariel Markowitz-Shulman, Associate Director of Strategic Planning, NORD
- 4:25pm Closing Remarks
Rebekah Palmer, patient
- 4:30pm Wrap Up and Next Steps
Debbie Drell, Director of Membership, NORD
Ariel Markowitz-Shulman, Associate Director of Strategic Planning, NORD
- 4:45pm Adjourn

Agenda subject to change.

